PPI-668 + BI 207127 + faldaprevir

This drug is an investigational oral combination regimen for **chronic hepatitis C virus (HCV) infection**. It consists of three direct-acting antivirals: - **PPI-668 (ravidasvir)**: a potent, pan-genotypic HCV NS5A inhibitor that blocks viral replication and assembly[1][2][3][5]. - **BI 207127 (deleobuvir)**: a non-nucleoside HCV NS5B polymerase inhibitor that interferes with the NS5B RNA-dependent RNA polymerase required for viral replication[1]. - **faldaprevir (BI 201335)**: an HCV NS3/4A protease inhibitor that prevents viral polyprotein cleavage essential for the viral life cycle[1]. The regimen was investigated in phase 2 clinical trials, showing high rates of rapid virologic response and sustained virologic response (SVR), even in patients with pre-existing resistance mutations. The primary indication is chronic hepatitis C, particularly genotype 1, and the therapy is interferon-free and all-oral, responding to the need for more effective and better-tolerated HCV regimens[1]. Developers are Presidio Pharmaceuticals (PPI-668), Boehringer Ingelheim (BI 207127 and faldaprevir), and initial originator XTL Biopharmaceuticals for PPI-668[1][3][5].

Other names

ravidasvir + deleobuvir + faldaprevir